
ELK Biotechnology FBN1 rabbit pAb
FBN1 rabbit pAb는 인간 Fibrillin-1 단백질을 인식하는 다클론 항체로, WB, IHC, IF, ELISA에 사용 가능. 고순도 IgG 형태로 안정적인 신호 검출 제공. 인간, 마우스, 랫트 반응성 확인. -20°C에서 장기 보관 가능.
- 판매단위
- pk
카탈로그
2개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다ELK Biotechnology · ELK Biotechnology FBN1 rabbit pAb
제품명
FBN1 rabbit pAb
기본 정보
| 항목 | 내용 |
|---|---|
| Alternative Names | FBN1; FBN; Fibrillin-1 |
| Applications | WB; IHC; IF; ELISA |
| Recommended Dilutions | Western Blot: 1/500 - 1/2000 Immunohistochemistry: 1/100 - 1/300 ELISA: 1/20000 Not yet tested in other applications |
| Immunogen | The antiserum was produced against synthesized peptide derived from human Fibrillin-1 (AA range: 2811–2860) |
| Host | Rabbit |
| Storage | -20°C / 1 year |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1 mg/ml |
| GeneID (Human) | 2200 |
| Human Swiss-Prot No | P35555 |
| Species Reactivity | Human; Mouse; Rat |
세포 내 위치
Secreted. Fibrillin-1 and Asprosin chains are still linked together during secretion from cells, but are subsequently separated by furin (PubMed:24982166).
- Fibrillin-1: Secreted, extracellular space, extracellular matrix
- Asprosin: Secreted; secreted by white adipose tissue and circulates in the plasma.
배경 정보
This gene encodes a member of the fibrillin family of proteins. The encoded preproprotein is proteolytically processed to generate two proteins including the extracellular matrix component fibrillin-1 and the protein hormone asprosin.
Fibrillin-1 is an extracellular matrix glycoprotein that serves as a structural component of calcium-binding microfibrils, providing force-bearing structural support in elastic and nonelastic connective tissues throughout the body.
Asprosin, secreted by white adipose tissue, regulates glucose homeostasis. Mutations in this gene are associated with Marfan syndrome, MASS phenotype, ectopia lentis syndrome, Weill-Marchesani syndrome, Shprintzen-Goldberg syndrome, and neonatal progeroid syndrome. (RefSeq, Apr 2016)
ELK Biotechnology 상품 둘러보기
전체보기문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.
